Insights - Novavax (NVAX) reported Phase 3 from their US/Mexico trial and the data confirmed their vaccine as best in class. Novavax provided 90% overall protection and 100% protection … Continue Reading
Premium: Read NowInsights - The biotech market (XBI) is up over 4% today on news that the FDA approved Biogen’s aducanumab for Alzheimer’s Disease. It is the first new … Continue Reading
Premium: Read NowInsights - Magenta (MGTA) released more patient data at ASCO from their Phase 2 in mobilizing Multiple Myeloma patients. Remember, a few weeks ago, the abstract had data on 10 Multiple Myeloma patients … Continue Reading
Premium: Read NowInsights - Magenta reported preliminary data from their Phase 2 in mobilizing Multiple Myeloma patients and it was phenomenal. Concurrently, with the data announcement, Magenta also closed a $86M financing with … Continue Reading
Premium: Read NowInsights - Yesterday, Magenta (MGTA) competitor Jasper merged with SPAC company Amplitude Healthcare (AMHC). As part of transaction, Jasper will have a $490M valuation with a cash … Continue Reading
Premium: Read NowInsights - Yesterday, President Biden backed a proposed waiver for COVID-19 vaccine intellectual property rights. This would allow generic manufacturing of the vaccines and increase vaccine accessibility … Continue Reading
Premium: Read NowInsights - It has been an eventful week for Novavax (NVAX), and we believe the news flow will spill over into next week. Biden’s Speech Included NovavaxOn … Continue Reading
Premium: Read Now
